rMenB+OMV NZ vaccine

BIOLOGICAL3 trials

Sponsors

GlaxoSmithKline

Conditions

Infections, MeningococcalMeningitisMeningitis, Meningococcal

Phase 3

Effectiveness of GlaxoSmithKline Biologicals S.A's Meningococcal Group B and Combined ABCWY Vaccines in Healthy Adolescents and Young Adults

CompletedNCT04502693

GlaxoSmithKlineInfections, Meningococcal

Start: 2020-08-14End: 2022-09-13Updated: 2024-03-05

A Phase 3 Study to Assess the Immune Response And Safety Of Rmenb+Omv Nz In Primed Healthy Participants (10 To 20 Years Old)

CompletedNCT06995430

GlaxoSmithKlineMeningitis

Start: 2025-07-07End: 2025-12-15Updated: 2026-04-21

Phase 4

A Sourcing Study to Collect Human Blood Samples From Healthy Adults

CompletedNCT03493919

GlaxoSmithKlineMeningitis, Meningococcal

Start: 2018-03-08End: 2022-05-27Updated: 2023-07-17

Related Papers

Breadth of immune response, immunogenicity, reactogenicity, and safety for a pentavalent meningococcal ABCWY vaccine in healthy adolescents and young adults: results from a phase 3, randomised, controlled observer-blinded trial.

2024-12-056 citations